Procept BioRobotics Corp

Cash, cash equivalents and restricted cash balances as of June 30, 2025, totaled $305.8, while long-term borrowings totaled $52.0 million.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

All statements other than statements of historical facts contained in this Quarterly Report, including without limitation statements regarding our business model and strategic plans for our products, technologies and business, including our implementation thereof, the timing of and our ability to obtain and maintain regulatory approvals, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the commercial success and market acceptance of our products, the sufficiency of our cash, cash equivalents and short-term investments, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.

SEC original ↗Procept BioRobotics Corp — 10-Q Quarterly report10-QAug 5, 2026

The carrying value of the Company s long-term debt approximates fair value as the debt bears interest at variable SOFR rates at June 30, 2026 and December 31, 2025, which is observable at commonly quoted intervals for the full term of the loan, and therefore, is considered a Level 2 item in the fair value hierarchy.

SEC original ↗Procept BioRobotics Corp — 10-Q Quarterly report10-QAug 5, 2026

Long-Term Debt Term Loan Facility In October 2022, the Company entered into a loan and security agreement (as amended, the Agreement ) with Canadian Imperial Bank of Commerce, or CIBC.

SEC original ↗Procept BioRobotics Corp — 10-Q Quarterly report10-QAug 5, 2026

The Agreement provides for a senior secured term loan facility in the aggregate principal amount of $ 52.0 million (the "Term Loan Facility") which was borrowed in full.

SEC original ↗Procept BioRobotics Corp — 10-Q Quarterly report10-QAug 5, 2026

The Term Loan Facility is scheduled to mature on the fifth anniversary of the closing date (the Maturity Date ).

SEC original ↗Procept BioRobotics Corp — 10-Q Quarterly report10-QAug 5, 2026

, August 6, 2025 -- PROCEPT BioRobotics Corporation (Nasdaq PRCT) (the Company ), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Throughout the second quarter, we remained focused on expanding utilization of Aquablation therapy in the U.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

We believe these initiatives position us well for sustained growth and long-term value creation.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Gross margin expansion in the second quarter was due to improved operational efficiencies and overhead absorption, along with higher average selling prices on U.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, clinical trial outcomes, the Company s possible or assumed future results of operations, including descriptions of the Company s revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Should global tariff rates remain at current levels, the Company estimates a potential gross margin headwind of approximately $1.0 to $2.0 million.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Forward Looking Statements This release contains forward looking statements within the meaning of federal securities laws, including with respect to the Company s projected financial performance for full year 2025, statements regarding the potential utilities, values, benefits and advantages of Aquablation therapy performed using PROCEPT BioRobotics products, including AquaBeam or Hydros Robotic Systems, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Forward-looking statements are only predictions based on the Company s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

These forward looking statements are based on the Company s current expectations and inherently involve significant risks and uncertainties.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025

These risks and uncertainties are described more fully in the section titled Risk Factors in the Company s filings with the Securities and Exchange Commission (the SEC ), including the Company s annual report on Form 10-K filed with the SEC on February 27, 2025, and amended on April 11, 2025, and subsequent quarterly reports on Form 10-Q.

SEC original ↗Procept BioRobotics Corp — Earnings release (8-K exhibit)EX-99Aug 6, 2025